Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

F2A sequence linking MGMTP140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells

Abstract

Chemoprotection of haematopoietic stem cells (HSCs) by gene therapeutic transfer of drug-resistance genes represents the encouraging approach to prevent myelosuppression, which is one of the most severe side effects in tumor therapy. Thus, we cloned and evaluated six different bicistronic lentiviral SIN vectors encoding two transgenes, MGMTP140K (an O6-benzylguanine-resistant mutant of methylguanine-DNA methyltransferase) and MDR1 (multidrug resistance 1), using various linker sequences (IRESEMCV, IRESFMDV and 2A-element of FMDV (F2A)). Expression of both transgenes in HL-60 and in K562 cells was assayed by quantitative real-time PCR. Combination therapy with ACNU plus paclitaxel in HL-60 cells and with carmustin (BCNU) plus doxorubicin in K562 cells resulted in the most significant survival advantage of cells transduced with the lentiviral vector HR’SIN-MGMTP140K-F2A-MDR1 compared with untransduced cells. In human HSCs, overexpression of both transgenes by this vector also caused significantly increased survival and enrichment of transduced cells after treatment with BCNU plus doxorubicin or temozolomide plus paclitaxel. In summary, we could show significant chemoprotection by overexpression of MDR1 and MGMTP140K with a lentiviral vector using the F2A linker element in two different haematopoietic cell lines and in human primary HSCs with various combination regimens. Consequently, we are convinced that these in vitro investigations will help to improve combination chemotherapy regimens by reducing myelotoxic side effects and increasing the therapeutic efficiency.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Daniel D, Crawford J . Myelotoxicity from chemotherapy. Semin Oncol 2006; 33: 74–85.

    Article  CAS  Google Scholar 

  2. Skipper HE . Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971; 28: 1479–1499.

    Article  CAS  Google Scholar 

  3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258–2266.

    Article  Google Scholar 

  4. Laufs S, Buss EC, Zeller WJ, Fruehauf S . Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option? Drug Resist Updat 2003; 6: 57–69.

    Article  CAS  Google Scholar 

  5. Sorrentino BP . Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev 2002; 2: 431–441.

    Article  CAS  Google Scholar 

  6. Gottesman MM, Pastan I . Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427.

    Article  CAS  Google Scholar 

  7. Chaudhary PM, Roninson IB . Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94.

    Article  CAS  Google Scholar 

  8. Pegg AE . Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119–6129.

    CAS  Google Scholar 

  9. Erickson LC, Laurent G, Sharkey NA, Kohn KW . DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980; 288: 727–729.

    Article  CAS  Google Scholar 

  10. Isobe K, Kobayashi K, Kosaihira S, Kurimoto F, Sakai H, Uchida Y et al. Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer. Lung Cancer 2009; 66: 350–354.

    Article  Google Scholar 

  11. Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P et al. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs 2008; 26: 553–559.

    Article  CAS  Google Scholar 

  12. Yoon C, Papadopoulos NE, Camacho LH, McIntyre S, Alvarado GC, Bedikian AY et al. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma Res 2010; 20: 43–47.

    Article  CAS  Google Scholar 

  13. Schiedlmeier B, Schilz AJ, Kuhlcke K, Laufs S, Baum C, Zeller WJ et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum Gene Ther 2002; 13: 233–242.

    Article  CAS  Google Scholar 

  14. Hanania EG, Fu S, Roninson I, Zu Z, Deisseroth AB . Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 1995; 2: 279–284.

    CAS  PubMed  Google Scholar 

  15. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992; 89: 9676–9680.

    Article  CAS  Google Scholar 

  16. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103.

    Article  CAS  Google Scholar 

  17. Hibino H, Tani K, Ikebuchi K, Wu MS, Sugiyama H, Nakazaki Y et al. The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. Blood 1999; 93: 2839–2848.

    CAS  PubMed  Google Scholar 

  18. Licht T, Haskins M, Henthorn P, Kleiman SE, Bodine DM, Whitwam T et al. Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci USA 2002; 99: 3123–3128.

    Article  CAS  Google Scholar 

  19. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996; 93: 15346–15351.

    Article  CAS  Google Scholar 

  20. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165–172.

    Article  CAS  Google Scholar 

  21. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94: 52–61.

    CAS  PubMed  Google Scholar 

  22. Takahashi S, Aiba K, Ito Y, Hatake K, Nakane M, Kobayashi T et al. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. Cancer Sci 2007; 98: 1609–1616.

    Article  CAS  Google Scholar 

  23. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP . Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005; 105: 997–1002.

    Article  CAS  Google Scholar 

  24. Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003; 112: 1581–1588.

    Article  CAS  Google Scholar 

  25. Larochelle A, Choi U, Shou Y, Naumann N, Loktionova NA, Clevenger JR et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest 2009; 119: 1952–1963.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J et al. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res 2008; 68: 6171–6180.

    Article  CAS  Google Scholar 

  27. Southgate TD, Garside E, Margison GP, Fairbairn LJ . Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase. J Gene Med 2006; 8: 972–979.

    Article  CAS  Google Scholar 

  28. Wang J, Chen Z, Xia X, Lu D, Xue J, Ruan C . Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk Res 2002; 26: 281–288.

    Article  Google Scholar 

  29. Jelinek J, Rafferty JA, Cmejla R, Hildinger M, Chinnasamy D, Lashford LS et al. A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Ther 1999; 6: 1489–1493.

    Article  CAS  Google Scholar 

  30. Suzuki M, Sugimoto Y, Tsukahara S, Okochi E, Gottesman MM, Tsuruo T . Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy. Clin Cancer Res 1997; 3: 947–954.

    CAS  PubMed  Google Scholar 

  31. Maier P, Spier I, Laufs S, Veldwijk MR, Fruehauf S, Wenz F et al. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K). Gene Ther 2010; 17: 389–399.

    Article  CAS  Google Scholar 

  32. Xu-Welliver M, Kanugula S, Pegg AE . Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res 1998; 58: 1936–1945.

    CAS  PubMed  Google Scholar 

  33. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T . IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000; 1: 376–382.

    Article  CAS  Google Scholar 

  34. Szymczak AL, Vignali DA . Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 2005; 5: 627–638.

    Article  CAS  Google Scholar 

  35. Donnelly ML, Gani D, Flint M, Monaghan S, Ryan MD . The cleavage activities of aphthovirus and cardiovirus 2A proteins. J Gen Virol 1997; 78 (Part 1): 13–21.

    Article  CAS  Google Scholar 

  36. Donnelly ML, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D et al. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol 2001; 82 (Part 5): 1027–1041.

    Article  CAS  Google Scholar 

  37. Hahn H, Palmenberg AC . Deletion mapping of the encephalomyocarditis virus primary cleavage site. J Virol 2001; 75: 7215–7218.

    Article  CAS  Google Scholar 

  38. Maier P, Herskind C, Fleckenstein K, Spier I, Laufs S, Zeller WJ et al. MDR1 gene transfer using a lentiviral SIN vector confers radioprotection to human CD34+ hematopoietic progenitor cells. Radiat Res 2008; 169: 301–310.

    Article  CAS  Google Scholar 

  39. Santoni de Sio FR, Gritti A, Cascio P, Neri M, Sampaolesi M, Galli C et al. Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells 2008; 26: 2142–2152.

    Article  CAS  Google Scholar 

  40. Schiedlmeier B, Kuhlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S . Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 2000; 95: 1237–1248.

    CAS  PubMed  Google Scholar 

  41. Liu L, Lee K, Schupp J, Koc ON, Gerson SL . Heterogeneity of O6-alkylguanine-DNA-alkyltransferase measured by flow cytometric analysis in blood and bone marrow mononuclear cells. Clin Cancer Res 1998; 4: 475–481.

    CAS  PubMed  Google Scholar 

  42. Giordano FA, Sorg UR, Appelt JU, Lachmann N, Bleier S, Roeder I et al. Clonal inventory screens uncover monoclonality following serial transplantation of MGMTP140K transduced stem cells and dose-intense chemotherapy. Hum Gene Ther 2011; 22: 697–710.

    Article  CAS  Google Scholar 

  43. Bleier S, Maier P, Allgayer H, Wenz F, Zeller WJ, Fruehauf S et al. Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy. J Virol 2008; 82: 2448–2455.

    Article  CAS  Google Scholar 

  44. Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.

    Article  CAS  Google Scholar 

  45. Fruehauf S, Breems DA, Knaan-Shanzer S, Brouwer KB, Haas R, Lowenberg B et al. Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum Gene Ther 1996; 7: 1219–1231.

    Article  CAS  Google Scholar 

  46. Berghmans T, Lafitte JJ, Lecomte J, Alexopoulos CG, Van Cutsem O, Giner V et al. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer 2007; 96: 1644–1649.

    Article  CAS  Google Scholar 

  47. Postmus PE . Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest 1998; 113 (1 Suppl): 28S–31S.

    Article  CAS  Google Scholar 

  48. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  49. Azzabi A, Hughes AN, Calvert PM, Plummer ER, Todd R, Griffin MJ et al. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. Br J Cancer 2005; 92: 1006–1012.

    Article  CAS  Google Scholar 

  50. Ferlini C, Distefano M, Pierelli L, Bonanno G, Fattorossi A, Battaglia A et al. A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development. Pharmacol Toxicol 2001; 89: 231–236.

    Article  CAS  Google Scholar 

  51. Flasshove M, Moritz T, Bardenheuer W, Seeber S . Hematoprotection by transfer of drug-resistance genes. Acta Haematol 2003; 110: 93–106.

    Article  CAS  Google Scholar 

  52. De Vita S, De Matteis S, Laurenti L, Chiusolo P, Reddiconto G, Fiorini A et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 2005; 84: 760–762.

    Article  Google Scholar 

  53. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M . Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 2011; 127: 1356–1359.

    Article  CAS  Google Scholar 

  54. Naldini L . Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011; 12: 301–315.

    Article  CAS  Google Scholar 

  55. Wong ET, Ngoi SM, Lee CG . Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Ther 2002; 9: 337–344.

    Article  CAS  Google Scholar 

  56. Hennecke M, Kwissa M, Metzger K, Oumard A, Kroger A, Schirmbeck R et al. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res 2001; 29: 3327–3334.

    Article  CAS  Google Scholar 

  57. Borman AM, Le Mercier P, Girard M, Kean KM . Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res 1997; 25: 925–932.

    Article  CAS  Google Scholar 

  58. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–672.

    Article  CAS  Google Scholar 

  59. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181–2187.

    Article  CAS  Google Scholar 

  60. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401–409.

    Article  CAS  Google Scholar 

  61. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132–3142.

    Article  CAS  Google Scholar 

  62. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143–3150.

    Article  CAS  Google Scholar 

  63. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964–975.

    Article  CAS  Google Scholar 

  64. Giordano FA, Appelt JU, Zucknick M, Abba M, Zeller WJ, Fruehauf S et al. Cold spots in hot spots: transcription start sites of active genes are spared from HIV vector integration. AIDS 2009; 23: 2535–2537.

    Article  Google Scholar 

  65. Chung JH, Bell AC, Felsenfeld G . Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci USA 1997; 94: 575–580.

    Article  CAS  Google Scholar 

  66. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718–725.

    Article  CAS  Google Scholar 

  67. Ellis J . Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005; 16: 1241–1246.

    Article  CAS  Google Scholar 

  68. Herbst F, Ball CR, Tuorto F, Nowrouzi A, Wang W, Zavidij O et al. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther 2012; 20: 1014–1021.

    Article  CAS  Google Scholar 

  69. Zhang F, Frost AR, Blundell MP, Bales O, Antoniou MN, Thrasher AJ . A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010; 18: 1640–1649.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The technical assistance of Bernhard Berkus, Hans-Jürgen Engel and Sigrid Heil (DKFZ) are gratefully acknowledged. We thank Dr Sven Becker and Eva Stork of Cytonet GmbH, Heidelberg, and Dr Eike Buss of Department of Internal Medicine V, University of Heidelberg for making available leukapheresis samples. This work was supported in part by grants from the Deutsche Krebshilfe/Dr Mildred-Scheel-Stiftung (10-2089-FI 1).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Maier.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary information accompanies the paper on Cancer Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maier, P., Heckmann, D., Spier, I. et al. F2A sequence linking MGMTP140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Ther 19, 802–810 (2012). https://doi.org/10.1038/cgt.2012.67

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2012.67

Keywords

This article is cited by

Search

Quick links